Sarepta Therapeutics (SRPT) News Today

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) shares have moved today as investors digest a mix of analyst upgrades, upcoming earnings, restructuring plans and a wave of securities-fraud class-action filings.

• Positive Sentiment: American Banking & News reports that a Piper Sandler analyst expects Sarepta’s stock price to rise, reflecting optimism on the company’s prospects. Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Expected to Rise, Piper Sandler Analyst Says
• Positive Sentiment: Oppenheimer upgrades SRPT’s rating, signaling growing confidence among equity analysts. Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by Oppenheimer
• Positive Sentiment: Sanford C. Bernstein initiates coverage on SRPT, providing fresh analyst research and potentially boosting trading interest. Sarepta Therapeutics (NASDAQ:SRPT) Coverage Initiated at Sanford C. Bernstein
• Positive Sentiment: MarketBeat notes unusually high trading volume following a recent analyst upgrade, suggesting investor enthusiasm for SRPT’s outlook. Sarepta Therapeutics (NASDAQ:SRPT) Sees Unusually-High Trading Volume Following Analyst Upgrade
• Positive Sentiment: Stock investors purchased nearly 22,000 call options on SRPT—up 54% versus average—indicating bullish sentiment among options traders. Stock Traders Buy High Volume of Sarepta Therapeutics Call Options (NASDAQ:SRPT)
• Neutral Sentiment: Sarepta will report Q2 2025 financial results on August 6, 2025, but will forgo a conference call this quarter. Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results
• Neutral Sentiment: MarketBeat reminds investors that SRPT will release its Q2 earnings before the market opens on August 6. Sarepta Therapeutics (SRPT) to Release Earnings on Wednesday
• Negative Sentiment: Sarepta announced a major restructuring—including a 36% workforce reduction—to save roughly $400 million annually, and agreed to add an FDA black-box warning for acute liver injury and failure on its ELEVIDYS gene therapy label after the EMA recommended refusing marketing authorization. Sarepta Therapeutics (SRPT) Announces Restructuring and ELEVIDYS Black Box Warning, EMA Recommends Refusal of Marketing Authorization, Securities Class Action Pending – Hagens Berman
• Negative Sentiment: Shares plunged after the third patient death in a Sarepta gene-therapy trial, exacerbating concerns over safety and triggering another securities-fraud class action. Sarepta Therapeutics (SRPT) Tanks 36% After 3rd Patient Death, SRPT Securities Class Action Pending - Hagens Berman
• Negative Sentiment: Bronstein, Gewirtz & Grossman notifies investors of a class action against Sarepta and certain officers, highlighting alleged misconduct and potential liability. SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
• Negative Sentiment: Levi & Korsinsky files a securities class action seeking to recover losses from alleged fraud between June 2023 and June 2025. Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Seeking Recovery for Investors - Contact Levi & Korsinsky
• Negative Sentiment: BFA Law reminds SRPT investors of the August 25 deadline to join a class action over recent stock drops. SRPT INVESTOR REMINDER: Sarepta Therapeutics, Inc. Stock Drop Leads to Class Action – Investors with Losses Urged to Contact BFA Law by August 25 (NASDAQ:SRPT)
• Negative Sentiment: Pomerantz LLP issues an investor alert on an SRPT class action and upcoming filing deadlines. INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT
• Negative Sentiment: Levi & Korsinsky reiterates its class-action suit over alleged securities law violations dating back to June 2023. Sarepta Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SRPT
• Negative Sentiment: The Gross Law Firm warns shareholders of an August 25 deadline to seek lead-plaintiff status in the SRPT securities lawsuit. The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 25, 2025 in Sarepta Therapeutics, Inc. Lawsuit - SRPT
• Negative Sentiment: The DJS Law Group reminds investors of their right to lead a class action over alleged 10b-5 violations. SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT
• Negative Sentiment: The Schall Law Firm issues an alert for investors to join a securities-fraud suit under Sections 10(b) and 20(a). SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm